Trial Profile
A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab (MK-3475) for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 31 Aug 2023 Status changed from active, no longer recruiting to completed.
- 08 Dec 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.
- 05 Jan 2021 Planned primary completion date changed from 1 Sep 2020 to 1 Jun 2021.